NaPro/Abbott Paclitaxel Licenses Settle Patent Dispute, Create “Tripwires”
Executive Summary
NaPro Biotherapeutics' annual paclitaxel capacity will reach 100 kg by the time of the expected U.S. launch in early 2002, CEO Leonard Shaykin said Nov. 30